Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
about
Update on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphoma90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma.Ibritumomab tiuxetan for non-Hodgkin's lymphoma.Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma.Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma.Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab.Current treatment options in aggressive lymphoma.Nursing a patient during and after 90Y-ibritumomab tiuxetan (Zevalin) therapy.Tailoring antibodies for radionuclide delivery.Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies.Epratuzumab in the therapy of oncological and immunological diseases.Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies.Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects.Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report.Monoclonal Antibodies in Cancer Therapy: Mechanisms, Successes and Limitations.Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan.Long-term follow-up of (90)Y-ibritumomab-tiuxetan ((90)YIT) in the conditioning of autologous hematopoietic transplantation for indolent and mantle cell lymphomas in a single French center.Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma.
P2860
Q24633710-169346E0-D4DD-4BAA-913F-1D09DF62E995Q33361773-0033C5A5-8C00-46EA-9415-D97114949759Q33371489-C497F5BB-11A3-470F-A10E-772B2A42EA7BQ33376503-0302E939-26D8-4CD6-8DBA-85A510F20F19Q33685903-FA52CBA0-5E0A-4103-8663-BE1495C6C5CCQ34567445-BE32A3D9-85D5-48F9-AC43-DB72CED17EACQ34631795-0ED23ED6-3457-4C9F-969D-03A7F4F2C402Q35778926-29FEE44C-0225-4012-8E20-16CC2DE8D17AQ35778937-3B1630B5-7DF2-4CBA-9C01-29625CA3EA0AQ36349687-A2F9DD0F-580F-469B-ADFB-CB4A5EA82DA9Q36426877-A55967E8-E93E-47AA-9E7D-EB71F096EF8BQ36636619-8E5D6879-C73C-4F9D-9A4F-007C091AFC85Q36832137-98B173AA-B240-46E5-ACF8-8C31CDDC1C90Q37586857-7C89F964-E739-4AEC-8156-CD905AD3004AQ37877728-FDE51A76-3A68-4F1C-8A65-C09C782B0EB8Q38388962-1D44D262-068C-47BB-8FCB-6FDE7ECAF01FQ46830766-1F4A335E-DC8F-420C-B265-6F3BE39896FEQ53726732-36DDD21E-9AB9-4538-A968-03D44C00CF7AQ55689230-765D4AB2-42FA-4827-B293-CC05B86E5C9D
P2860
Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Subsequent chemotherapy regime ...... an for non-Hodgkin's lymphoma.
@ast
Subsequent chemotherapy regime ...... an for non-Hodgkin's lymphoma.
@en
type
label
Subsequent chemotherapy regime ...... an for non-Hodgkin's lymphoma.
@ast
Subsequent chemotherapy regime ...... an for non-Hodgkin's lymphoma.
@en
prefLabel
Subsequent chemotherapy regime ...... an for non-Hodgkin's lymphoma.
@ast
Subsequent chemotherapy regime ...... an for non-Hodgkin's lymphoma.
@en
P2093
P356
P1476
Subsequent chemotherapy regime ...... an for non-Hodgkin's lymphoma.
@en
P2093
Gregory A Wiseman
Kay M Ristow
Stephen M Ansell
Thomas E Witzig
Thomas M Habermann
P304
P356
10.1200/JCO.2002.10.143
P407
P577
2002-09-01T00:00:00Z